Fulgent Genetics (FLGT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FLGT SEC filings page.
Fulgent Genetics, Inc. (FLGT) reported $323.9M in revenue over the twelve months to Jun 30, 2026, up 6.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The revenue recovery and better gross margins have not yet overcome negative cash conversion and a costly operating base.
The earnings recovery is not yet a cash recovery: operating cash flow flipped from$21.1M in FY2024 to-$101.6M in FY2025. Free cash flow also moved from-$19.3M to-$124.2M , showing the deterioration reached both cash from operations and cash after capital spending.
Revenue increased
SG&A grew
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Fulgent Genetics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Fulgent Genetics, Inc. has an operating margin of -28.2%, meaning the company loses $28 on every $100 of revenue. This results in a profitability score of 7/100. This is down from -26.1% the prior year.
Fulgent Genetics, Inc.'s revenue grew 13.8% year-over-year to $322.7M, a solid pace of expansion. This earns a growth score of 52/100.
With a current ratio of 6.48, Fulgent Genetics, Inc. holds $6.48 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 95/100.
Fulgent Genetics, Inc.'s operations used $101.6M of cash, and capex of $22.6M added to the outflow, for a free cash flow shortfall of $124.2M. This results in a cash flow score of 9/100.
Fulgent Genetics, Inc. posts a -5.4% return on equity (ROE), meaning it loses $5 for every $100 of shareholders' equity. This results in a returns score of 15/100. This is down from -3.8% the prior year.
Fulgent Genetics, Inc. scores 4.29, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $569.6M against total liabilities of $106.8M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Fulgent Genetics, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Fulgent Genetics, Inc. reported a net loss of $60.5M while operations used $101.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Fulgent Genetics, Inc. reported an operating loss of $91.1M against $75K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Fulgent Genetics, Inc. generated $85.4M in revenue in Q2 2026. This represents an increase of 4.4% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.
Fulgent Genetics, Inc.'s EBITDA was -$28.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Fulgent Genetics, Inc. reported a net loss of $29.5M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Fulgent Genetics, Inc. earned -$1.05 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Fulgent Genetics, Inc. recorded an outflow of $27.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 1557.3%.
Fulgent Genetics, Inc. held $26.3M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Fulgent Genetics, Inc.'s gross margin was 30.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 12.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.
Fulgent Genetics, Inc.'s operating margin was -42.3% in Q2 2026, reflecting core business profitability. This is down 18.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.4 percentage points.
Fulgent Genetics, Inc.'s net profit margin was -34.6% in Q2 2026, showing the share of revenue converted to profit. This is down 11.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.
Fulgent Genetics, Inc.'s quarterly ROE was -2.9% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.
Capital Allocation
Fulgent Genetics, Inc. invested $14.6M in research and development in Q2 2026. This represents an increase of 8.0% from the same quarter a year earlier. Against the prior quarter it is up 2.7%.
Fulgent Genetics, Inc. spent $23.8M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 979.6% from the same quarter a year earlier. Against the prior quarter it is down 40.6%.
Fulgent Genetics, Inc. invested $3.9M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 43.5% from the same quarter a year earlier. Against the prior quarter it is down 25.8%.
FLGT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $85.4M+4.4% | $71.1M-3.2% | $83.3M+9.3% | $84.1M+17.2% | $81.8M+15.2% | $73.5M+13.9% | $76.2M+8.1% | $71.7M-15.3% |
| Cost of Revenue | $59.7M+26.1% | $49.6M+10.0% | $50.8M+14.4% | $48.6M+8.0% | $47.4M+6.4% | $45.1M+6.5% | $44.4M-2.0% | $45.0M+0.3% |
| Gross Profit | $25.7M-25.4% | $21.5M-24.2% | $32.6M+2.3% | $35.5M+32.7% | $34.4M+30.0% | $28.3M+28.2% | $31.8M+26.2% | $26.8M-32.8% |
| R&D Expenses | $14.6M+8.0% | $14.2M+14.4% | $14.2M+17.0% | $13.9M+17.6% | $13.5M0.0% | $12.4M+8.4% | $12.1M+1.3% | $11.8M+17.7% |
| SG&A Expenses | $42.4M+9.7% | $39.9M+18.2% | $52.6M+55.3% | $35.0M+16.3% | $38.7M+29.3% | $33.8M+10.8% | $33.9M-19.7% | $30.1M+8.7% |
| Operating Income | -$36.1Mn/m | -$34.6Mn/m | -$36.2Mn/m | -$15.3Mn/m | -$19.7Mn/m | -$19.8Mn/m | -$16.1Mn/m | -$17.1M-8080.8% |
| EBITDA | -$28.4Mn/m | -$28.6Mn/m | -$30.0Mn/m | -$9.3Mn/m | -$13.7Mn/m | -$13.9Mn/m | -$9.9Mn/m | -$11.2M-268.2% |
| Interest Expense | $59K+247.1% | $17K+21.4% | $16K-60.0% | $28K+100.0% | $17K-32.0% | $14Kn/m | $40K-51.2% | $14K-80.0% |
| Income Tax | $29Kn/m | -$704K-500.0% | -$5.6Mn/m | -$683Kn/m | -$2.3Mn/m | $176Kn/m | -$1.8Mn/m | -$3.8M-118.9% |
| Net Income | -$29.5Mn/m | -$24.8Mn/m | -$23.4Mn/m | -$6.6Mn/m | -$19.0Mn/m | -$11.5Mn/m | -$5.9Mn/m | -$14.6Mn/m |
| EPS (Basic) | -$1.05n/m | -$0.80n/m | -$0.76n/m | -$0.21n/m | -$0.62n/m | -$0.37n/m | -$0.19n/m | -$0.48n/m |
| EPS (Diluted) | -$1.05n/m | -$0.80n/m | -$0.76n/m | -$0.21n/m | -$0.62n/m | -$0.37n/m | -$0.19n/m | -$0.48n/m |
| Diluted Shares (Avg) | 28M-8.3% | 31M+0.2% | N/A | 31M+1.1% | 31M+1.5% | 31M+3.6% | N/A | 30M+1.3% |
FLGT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B-9.2% | $1.2B-4.1% | $1.2B-0.5% | $1.2B-1.6% | $1.2B-2.6% | $1.2B-2.0% | $1.2B-1.2% | $1.2B-9.2% |
| Current Assets | $454.8M+6.1% | $479.0M+14.9% | $550.5M+55.7% | $507.4M+55.4% | $428.7M+7.4% | $416.8M+7.8% | $353.6M-30.4% | $326.5M-40.6% |
| Cash & Equivalents | $26.3M-70.1% | $23.4M-65.2% | $50.2M-9.0% | $117.6M+102.7% | $87.9M+35.0% | $67.3M+23.1% | $55.1M-43.4% | $58.0M-31.0% |
| Short-Term Investments | $230.7Mn/m | $252.9Mn/m | $285.9M+40.9% | $0n/m | $0n/m | $0n/m | $203.0Mn/m | $0n/m |
| Inventory | $793K | $770K | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $64.9M-15.9% | $69.3M-3.1% | $84.8M+22.8% | $71.2M+24.2% | $77.2M+36.4% | $71.5M+37.3% | $69.0M+35.0% | $57.3M+16.3% |
| Long-Term Investments | $294.3M-39.3% | $328.3M-33.6% | $369.3M-35.3% | $411.8M-31.6% | $484.5M-7.9% | $494.1M-8.6% | $570.4M+34.7% | $602.2M+57.0% |
| Goodwill | $53.9M+144.2% | $53.7M+143.6% | $25.1M+13.7% | $25.1M+13.7% | $22.1M0.0% | $22.1M0.0% | $22.1M0.0% | $22.1M-84.5% |
| Total Liabilities | $93.2M+5.7% | $112.2M+35.2% | $106.8M+17.6% | $93.8M-5.1% | $88.2M-14.7% | $83.0M-19.6% | $90.8M-11.0% | $98.9M+2.4% |
| Current Liabilities | $71.8M+0.6% | $90.1M+36.7% | $85.0M+16.6% | $72.4M-2.1% | $71.3M-5.8% | $65.9M-13.2% | $72.9M-0.2% | $74.0M+20.5% |
| Non-Current Liabilities | $21.5M+27.4% | $22.1M+29.4% | $21.8M+22.0% | $21.4M-14.1% | $16.9M-39.0% | $17.1M-37.5% | $17.9M-38.3% | $24.9M-29.2% |
| Total Equity | $1.0B-10.3% | $1.0B-6.9% | $1.1B-1.9% | $1.1B-1.1% | $1.1B-1.4% | $1.1B-0.2% | $1.1B-0.3% | $1.1B-9.6% |
| Retained Earnings | $475.6M-15.1% | $505.1M-12.7% | $530.0M-10.2% | $553.4M-7.2% | $560.0M-8.4% | $578.9M-6.6% | $590.5M-6.7% | $596.4M-21.7% |
Not reported in any period shown, so not listed: Long-Term Debt.
FLGT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$23.8Mn/m | $7.1Mn/m | -$78.1M-412.3% | $11.1Mn/m | -$30.2M-804.1% | -$4.4M-161.0% | $25.0M+67.5% | -$15.5M-251.5% |
| Depreciation & Amortization | $7.7M+28.7% | $6.0M+1.4% | $6.1M-1.3% | $6.0M+1.5% | $6.0M-2.9% | $5.9M-11.2% | $6.2M-5.2% | $5.9M-7.8% |
| Stock-Based Compensation | $8.6M-14.1% | $9.9M-6.3% | N/A | $9.7M-11.0% | $10.0M-13.7% | $10.6M-8.4% | N/A | $10.9M+0.2% |
| Capital Expenditures | $3.9M-43.5% | $5.2M+10.3% | $5.0M+31.8% | $6.0M-69.0% | $6.8M-47.3% | $4.7M+16.3% | $3.8M+21.6% | $19.5M+296.9% |
| Free Cash Flow | -$27.6Mn/m | $1.9Mn/m | -$83.1M-491.4% | $5.1Mn/m | -$37.0Mn/m | -$9.1M-385.0% | $21.2M+79.6% | -$35.0M-759.1% |
| Investing Cash Flow | $50.8M-4.9% | $10.9M-60.6% | $11.2Mn/m | $19.1M+112.4% | $53.4M+631.2% | $27.7Mn/m | -$27.5M-213.1% | $9.0M-55.2% |
| Financing Cash Flow | -$24.2Mn/m | -$44.8Mn/m | -$534Kn/m | -$445Kn/m | -$2.6Mn/m | -$11.2Mn/m | -$327Kn/m | -$567Kn/m |
| Share Buybacks | $23.8M+979.6% | $40.1M+361.8% | $0n/m | $0n/m | $2.2Mn/m | $8.7M+3757.3% | $0-100.0% | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
FLGT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.1%-12.0pp | 30.2%-8.4pp | 39.1%-2.7pp | 42.2%+4.9pp | 42.1%+4.8pp | 38.6%+4.3pp | 41.8%+6.0pp | 37.3%-9.7pp |
| Operating Margin | -42.3%-18.1pp | -48.7%-21.7pp | -43.5%-22.3pp | -18.3%+5.5pp | -24.1%+2.5pp | -27.0%+6.9pp | -21.2% | -23.8%-24.1pp |
| Net Margin | -34.6%-11.4pp | -34.9%-19.2pp | -28.1%-20.4pp | -7.9%+12.6pp | -23.2%-10.9pp | -15.7%+5.2pp | -7.7% | -20.4%-4.9pp |
| Return on Equity | -2.9%-1.2pp | -2.4%-1.3pp | -2.1%-1.6pp | -0.6%+0.7pp | -1.7%-0.9pp | -1.0%+0.2pp | -0.5%+10.8pp | -1.3%-0.3pp |
| Return on Assets | -2.7%-1.1pp | -2.1%-1.2pp | -1.9%-1.5pp | -0.5%+0.7pp | -1.6%-0.9pp | -1.0%+0.1pp | -0.5%+9.9pp | -1.2%-0.2pp |
| Current Ratio | 6.34+0.3x | 5.31-1.0x | 6.48+1.6x | 7.01+2.6x | 6.01+0.7x | 6.32+1.2x | 4.85-2.1x | 4.41-4.5x |
| Liabilities-to-Equity | 0.090.0x | 0.110.0x | 0.100.0x | 0.080.0x | 0.080.0x | 0.070.0x | 0.080.0x | 0.090.0x |
| Asset Turnover | 0.080.0x | 0.060.0x | 0.070.0x | 0.070.0x | 0.070.0x | 0.060.0x | 0.060.0x | 0.060.0x |
| FCF Margin | -32.3%+12.9pp | 2.7%+15.1pp | -99.7%-127.6pp | 6.0%+54.9pp | -45.2%-33.0pp | -12.4%-17.4pp | 27.9%+11.1pp | -48.9%-55.1pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Fulgent Genetics, Inc. FLGT | FY2025 | $322.7M | -$60.5M | -18.8% | $569.6M | 43/100 |
| Castle Biosciences, Inc. CSTL | FY2025 | $344.2M | -$24.2M | -7.0% | $1.0B | 61/100 |
| Myriad Genetics Inc MYGN | FY2025 | $824.5M | -$365.9M | -44.4% | $575.8M | 45/100 |
| CareDx, Inc. CDNA | FY2025 | $379.8M | -$21.4M | -5.6% | $3.6B | 51/100 |
| Personalis, Inc. PSNL | FY2025 | $69.6M | -$81.3M | N/A | $1.7B | 51/100 |
| NeoGenomics, Inc. NEO | FY2025 | $727.3M | -$108.0M | -14.8% | $2.1B | 51/100 |
Where Fulgent Genetics, Inc. Ranks
Frequently Asked Questions
What is Fulgent Genetics, Inc.'s annual revenue?
Fulgent Genetics, Inc. (FLGT) reported $322.7M in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Fulgent Genetics, Inc.'s revenue growing?
Fulgent Genetics, Inc. (FLGT) revenue grew by 13.8% year-over-year, from $283.5M to $322.7M in fiscal year 2025.
Is Fulgent Genetics, Inc. profitable?
No, Fulgent Genetics, Inc. (FLGT) reported a net loss of $84.4M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $60.5M, with a net profit margin of -18.8%.
What is Fulgent Genetics, Inc.'s EBITDA?
Fulgent Genetics, Inc. (FLGT) had EBITDA of -$67.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Fulgent Genetics, Inc.'s gross margin?
Fulgent Genetics, Inc. (FLGT) had a gross margin of 40.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Fulgent Genetics, Inc.'s operating margin?
Fulgent Genetics, Inc. (FLGT) had an operating margin of -28.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Fulgent Genetics, Inc.'s net profit margin?
Fulgent Genetics, Inc. (FLGT) had a net profit margin of -18.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Fulgent Genetics, Inc.'s return on equity (ROE)?
Fulgent Genetics, Inc. (FLGT) has a return on equity of -5.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Fulgent Genetics, Inc.'s free cash flow?
Fulgent Genetics, Inc. (FLGT) recorded an outflow of $124.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Fulgent Genetics, Inc.'s operating cash flow?
Fulgent Genetics, Inc. (FLGT) recorded an outflow of $101.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Fulgent Genetics, Inc.'s total assets?
Fulgent Genetics, Inc. (FLGT) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Fulgent Genetics, Inc.'s capital expenditures?
Fulgent Genetics, Inc. (FLGT) invested $22.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Fulgent Genetics, Inc. spend on research and development?
Fulgent Genetics, Inc. (FLGT) invested $53.9M in research and development during fiscal year 2025.
What is Fulgent Genetics, Inc.'s current ratio?
Fulgent Genetics, Inc. (FLGT) had a current ratio of 6.48 as of fiscal year 2025, which is generally considered healthy.
What is Fulgent Genetics, Inc.'s liabilities-to-equity ratio?
Fulgent Genetics, Inc. (FLGT) had a liabilities-to-equity ratio of 0.10 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Fulgent Genetics, Inc.'s return on assets (ROA)?
Fulgent Genetics, Inc. (FLGT) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Fulgent Genetics, Inc.'s P/E ratio?
Fulgent Genetics, Inc. (FLGT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $569.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Fulgent Genetics, Inc.'s price-to-sales ratio?
Fulgent Genetics, Inc. (FLGT) trades at 1.8x sales, its market capitalization divided by $323.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $569.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Fulgent Genetics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Fulgent Genetics, Inc. (FLGT) held $705.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $101.6M over that year. Dividing the one by the other, the reported balance equals about 83 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Fulgent Genetics, Inc.'s Altman Z-Score?
Fulgent Genetics, Inc. (FLGT) has an Altman Z-Score of 4.29, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Fulgent Genetics, Inc.'s Piotroski F-Score?
Fulgent Genetics, Inc. (FLGT) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Fulgent Genetics, Inc.'s earnings high quality?
Fulgent Genetics, Inc. (FLGT) reported a net loss of $60.5M while operations used $101.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Fulgent Genetics, Inc. cover its interest payments?
Fulgent Genetics, Inc. (FLGT) reported an operating loss of $91.1M against $75K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Fulgent Genetics, Inc.?
Fulgent Genetics, Inc. (FLGT) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.